MCID: LRG016
MIFTS: 38

Large Intestine Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Large Intestine Adenocarcinoma

MalaCards integrated aliases for Large Intestine Adenocarcinoma:

Name: Large Intestine Adenocarcinoma 12 15
Adenocarcinoma of Large Intestine 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050913
UMLS 73 C1319315

Summaries for Large Intestine Adenocarcinoma

Disease Ontology : 12 A large intestine cancer that has material basis in epithelial cells of glandular origin.

MalaCards based summary : Large Intestine Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to cystic basal cell carcinoma and vaginal benign neoplasm. An important gene associated with Large Intestine Adenocarcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Large Intestine Adenocarcinoma

Diseases related to Large Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 cystic basal cell carcinoma 10.7 KRT20 KRT7
2 vaginal benign neoplasm 10.7 KRT20 KRT7
3 seminal vesicle adenocarcinoma 10.7 KRT20 KRT7
4 transverse colon cancer 10.7 KRT20 KRT7
5 appendix adenocarcinoma 10.7 KRT20 KRT7
6 ovarian large-cell neuroendocrine carcinoma 10.7 KRT20 KRT7
7 vaginal adenoma 10.7 KRT20 KRT7
8 vaginal tubulovillous adenoma 10.7 KRT20 KRT7
9 eyelid neoplasm 10.7 KRT20 KRT7
10 glandular cystitis 10.7 KRT20 KRT7
11 malignant syringoma 10.7 KRT20 KRT7
12 krukenberg carcinoma 10.7 KRT20 KRT7
13 small cell carcinoma of the bladder 10.7 KRT20 KRT7
14 eccrine sweat gland neoplasm 10.7 KRT20 KRT7
15 mucinous bronchioloalveolar adenocarcinoma 10.7 KRT20 KRT7
16 bile duct cystadenocarcinoma 10.7 KRT20 KRT7
17 intratubular embryonal carcinoma 10.7 KRT20 KRT7
18 ovarian mucinous adenocarcinoma 10.7 KRT20 KRT7
19 thymus adenocarcinoma 10.7 KRT20 KRT7
20 meibomian cyst 10.7 KRT20 KRT7
21 bladder lymphoma 10.7 KRT20 KRT7
22 papillary serous adenocarcinoma 10.7 KRT20 KRT7
23 jejunal adenocarcinoma 10.7 KRT20 KRT7
24 chronic cystitis 10.7 KRT20 KRT7
25 medulloepithelioma 10.7 KRT20 KRT7
26 glycogen-rich clear cell breast carcinoma 10.7 KRT20 KRT7
27 rectum adenocarcinoma 10.6 KRT20 KRT7
28 renal pelvis carcinoma 10.6 KRT20 KRT7
29 ampulla of vater neoplasm 10.6 KRT20 KRT7
30 appendix cancer 10.6 KRT20 KRT7
31 ampulla of vater adenocarcinoma 10.6 KRT20 KRT7
32 mucinous cystadenocarcinoma 10.6 KRT20 KRT7
33 biliary papillomatosis 10.6 KRT20 KRT7
34 endocervical adenocarcinoma 10.6 KRT20 KRT7
35 dermoid cyst 10.6 KRT20 KRT7
36 large cell acanthoma 10.6 KRT7 MTOR
37 immune system organ benign neoplasm 10.6 KRT20 KRT7
38 thymus lipoma 10.6 KRT20 KRT7
39 cystadenofibroma 10.6 KRT20 KRT7
40 ovarian mucinous neoplasm 10.6 KRT20 KRT7
41 cystic teratoma 10.6 KRT20 KRT7
42 horseshoe kidney 10.6 KRT20 KRT7
43 inverted papilloma 10.6 KRT20 KRT7
44 adenocarcinoma in situ 10.6 KRT20 KRT7
45 ovarian cystic teratoma 10.6 KRT20 KRT7
46 morpheaform basal cell carcinoma 10.6 CDH1 KRT20
47 pancreatic mucinous cystadenoma 10.6 KRT20 KRT7
48 kidney benign neoplasm 10.6 KRT7 MTOR
49 large cell neuroendocrine carcinoma 10.6 KRT20 KRT7
50 renal pelvis adenocarcinoma 10.6 CDH1 KRT7

Graphical network of the top 20 diseases related to Large Intestine Adenocarcinoma:



Diseases related to Large Intestine Adenocarcinoma

Symptoms & Phenotypes for Large Intestine Adenocarcinoma

GenomeRNAi Phenotypes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 CDH1 EIF4EBP1 KRT7 MCM3 MTOR

MGI Mouse Phenotypes related to Large Intestine Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.17 CDH1 CTNNB1 EIF4EBP1 KRT7 MCM3 MTOR

Drugs & Therapeutics for Large Intestine Adenocarcinoma

Drugs for Large Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925
2 Ferric Compounds Phase 4
3 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
4 Hepcidins Phase 4
5 Iron Supplement Nutraceutical Phase 4
6
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
7
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
8
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
10
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
11
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
12
Nicotine Approved Phase 3 54-11-5 942 89594
13
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
15
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
20 Antidotes Phase 3,Phase 2,Phase 1,Not Applicable
21 Calcium, Dietary Phase 3,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
25 Pharmaceutical Solutions Phase 3,Phase 2
26 Antibodies Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
30 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
31 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
33 Bone Density Conservation Agents Phase 3,Phase 2
34 Endothelial Growth Factors Phase 3,Phase 2
35 Immunoglobulin G Phase 3,Phase 2
36 Mitogens Phase 3,Phase 2,Phase 1
37 Formyltetrahydrofolates Phase 3
38 Tetrahydrofolates Phase 3
39 Mitomycins Phase 2, Phase 3
40 Folate Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
41 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
42
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
43
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
44
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
45
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
46
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
49
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
50
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
3 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
4 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
5 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
6 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
7 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
8 Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases. Recruiting NCT02758951 Phase 2, Phase 3 Perioperative systemic therapy
9 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Active, not recruiting NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
12 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Unknown status NCT02788006 Phase 2 Regorafenib 160 mg
13 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
14 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
15 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
16 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
17 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
19 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
21 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
22 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
23 Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma Completed NCT01479465 Phase 2 Simtuzumab;FOLFIRI;Placebo to match simtuzumab
24 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
25 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
26 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
27 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
28 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
29 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
30 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
31 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
32 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
33 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
34 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
35 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
36 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
37 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
38 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
39 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
40 Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Recruiting NCT03069950 Phase 2 Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
41 Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA) Recruiting NCT02738606 Phase 2 Chemotherapy
42 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting NCT03442569 Phase 2 Panitumumab;Nivolumab;Ipilimumab
43 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2
44 A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting NCT02599324 Phase 1, Phase 2 ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab
45 Regorafenib in Metastatic Colorectal Cancer Recruiting NCT02466009 Phase 2 Regorafenib
46 Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Recruiting NCT01876511 Phase 2 MK-3475;MK-3475
47 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Recruiting NCT03206073 Phase 1, Phase 2
48 TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting NCT03368963 Phase 1, Phase 2 Nanoliposomal Irinotecan;Trifluridine and Tipiracil Hydrochloride
49 Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer Recruiting NCT03043313 Phase 2 Tucatinib
50 Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Recruiting NCT03087071 Phase 2 Panitumumab;Trametinib

Search NIH Clinical Center for Large Intestine Adenocarcinoma

Genetic Tests for Large Intestine Adenocarcinoma

Anatomical Context for Large Intestine Adenocarcinoma

MalaCards organs/tissues related to Large Intestine Adenocarcinoma:

41
Liver, Colon, Lung, Endothelial, Kidney, Bone

Publications for Large Intestine Adenocarcinoma

Articles related to Large Intestine Adenocarcinoma:

# Title Authors Year
1
Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. ( 12647790 )
2003

Variations for Large Intestine Adenocarcinoma

Expression for Large Intestine Adenocarcinoma

Search GEO for disease gene expression data for Large Intestine Adenocarcinoma.

Pathways for Large Intestine Adenocarcinoma

Pathways related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 CDH1 CTNNB1 EIF4EBP1 MTOR
2
Show member pathways
12.26 CDH1 CTNNB1 MTOR
3 12.25 CDH1 KRT20 KRT7
4
Show member pathways
11.84 CDH1 CTNNB1 MTOR
5 11.69 CDH1 CTNNB1 MTOR
6
Show member pathways
11.68 EIF4EBP1 MTOR
7
Show member pathways
11.6 CTNNB1 EIF4EBP1 MTOR
8
Show member pathways
11.55 CDH1 CTNNB1 EIF4EBP1 MTOR
9 11.49 CTNNB1 EIF4EBP1 MTOR
10 11.35 EIF4EBP1 MTOR
11 11.33 CTNNB1 MTOR
12 11.25 EIF4EBP1 MTOR
13 11.21 CDH1 CTNNB1
14 11.16 CDH1 CTNNB1
15 11.15 CDH1 CTNNB1
16 11.07 EIF4EBP1 MTOR
17 11.04 CDH1 CTNNB1
18 10.99 CTNNB1 MTOR
19 10.97 EIF4EBP1 MTOR
20 10.91 EIF4EBP1 MTOR
21 10.85 CDH1 CTNNB1
22 10.66 EIF4EBP1 MTOR
23 10.07 CDH1 CTNNB1

GO Terms for Large Intestine Adenocarcinoma

Cellular components related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.16 CDH1 CTNNB1
2 apical junction complex GO:0043296 8.96 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of epithelial to mesenchymal transition GO:0010718 9.4 CTNNB1 MTOR
2 adherens junction organization GO:0034332 9.37 CDH1 CTNNB1
3 TOR signaling GO:0031929 9.32 EIF4EBP1 MTOR
4 regulation of osteoclast differentiation GO:0045670 9.26 CTNNB1 MTOR
5 regulation of myelination GO:0031641 9.16 CTNNB1 MTOR
6 entry of bacterium into host cell GO:0035635 8.96 CDH1 CTNNB1
7 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Sources for Large Intestine Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....